Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ken Coleman
AddedMar 31, 2024
UpdatedMay 31, 2026
Ken Coleman

Ken Coleman

Board Member, Biovia

Crunchbase

Ken Coleman's Career

Biovia
Biovia

San Diego, CA, US

Board Member· Board
Prevedere
Prevedere

Columbus, OH, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ken Coleman's Career

Biovia
Biovia
Acquired02001San Diego, CA, US
Board Member· Board

Leadership at Biovia

Peter G. SchultzPeter G. SchultzCo-Founder
Alejandro ZaffaroniAlejandro ZaffaroniCo-Founder
Jason BenedictJason BenedictCEO
Ricardo LevyRicardo LevyBoard Member
Larry R FergusonLarry R FergusonBoard Member

Similar to Biovia

SchrödingerSchrödingerNew York City, NY, USDrug Discovery, Softwareest. 1990SchrödingerNew York City, NY, US · est. 1990

Schrödinger, Inc.: A global life sciences firm specializing in drug discovery software.

Public · $567.2M787
Insightful ScienceInsightful ScienceSan Diego, CA, USBioinformatics, Softwareest. 2017Insightful ScienceSan Diego, CA, US · est. 2017

Insightful Science: A global full-stack software solutions provider for over 2M scientists.

Late Stage Private · $95M750
QuantumBioQuantumBioState College, PA, USDrug Discovery, Softwareest. 2002QuantumBioState College, PA, US · est. 2002

QuantumBio, based in State College, US, develops innovative drug discovery software for the life science industry.

Seed · $425k14
Drug Design MethodologiesDrug Design MethodologiesSt. Louis, MO, USDrug Design, Softwareest. 1998Drug Design MethodologiesSt. Louis, MO, US · est. 1998

Developing advanced software for efficient, cost-effective, and risk-free structure-based drug design in pharma and biotech.

Angel · $50k2
Prevedere
Prevedere
Series D$67.3M742012Columbus, OH, US
Board Member· Board

Leadership at Prevedere

Don FowlerDon FowlerBoard Member
Tamara SteffensTamara SteffensBoard Member
Dan FishbackDan FishbackBoard Member
Krish PanuKrish PanuBoard Member
Promod HaquePromod HaqueBoard Member
Pete ThomasPete ThomasBoard Member

Similar to Prevedere

PredataPredataNew York City, NY, USPredictive Analyticsest. 2015PredataNew York City, NY, US · est. 2015

NYC-based Predata leverages machine learning for predictive analytics in geopolitical risk management.

Seed · $3.3M24
PredictWisePredictWiseNew York City, NY, USAnalytics, Dataest. 2017PredictWiseNew York City, NY, US · est. 2017

SaaS platform offering swift, comprehensive insights into public opinion.

Seed · $250k6
PurePredictivePurePredictiveSandy, UT, USPredictive Modelingest. 2011PurePredictiveSandy, UT, US · est. 2011

PurePredictive: An AI software platform transforming data into revenue with advanced predictive modeling.

Series A · $10.2M30
PrecognatePrecognateAnalytics SoftwarePrecognate
Pre-Seed · $17k

Ken Coleman's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Ken Coleman

Joe BressJoe BressBoard Member · Albany Molecular Research Inc. - AmriRajesh NambiarRajesh NambiarBoard Member · TrizettoKenneth HaoKenneth HaoBoard Member · SplunkKoleman KarleskiKoleman KarleskiBoard Member · AfterbotJohann Schleier-SmithJohann Schleier-SmithBoard Member · SamaKen FrazierKen FrazierBoard Member · ExxonMobil